

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

TOUMAI LAPAROSCOPIC SURGICAL ROBOT OBTAINED THE EU CE MARK

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed Toumai® Laparoscopic Surgical Robot System (“**Toumai**”), which is applicable to laparoscopic surgeries in urology, general surgery, thoracic surgery and gynecology, has successfully obtained the EU CE mark, making it the first and only domestic laparoscopic surgical robot with the EU CE mark.

ABOUT TOUMAI

Toumai, a core product of the Company, is a laparoscopic surgical robot designed and developed by the Group for a wide range of surgical procedures, which enables complex surgeries by adopting a minimally invasive approach. The agility of robotic arms allows greater precision in operations, enhances the safety of surgery and reduces surgeon fatigue. Seated comfortably at the console, a surgeon views an immersive 3D HD image of the surgical field and manipulates the surgical instruments inside the patient’s body by controlling the robotic arms. Toumai provides surgeons with a range of motions analogous to those of human wrists, while filtering out the tremors inherent in human hands.

To date, Toumai has completed in aggregate nearly 3,000 multi-disciplinary clinical surgeries in more than 90 domestic and overseas medical institutions, including nearly 200 5G remote surgeries, providing patients and doctors with high-quality and affordable medical robot solutions. With its advanced technological innovation capability, stable product performance and well-established training and service system, Toumai has achieved the first overseas sales of domestic laparoscopic surgical robot and successfully moved

onto the clinical application stage, creating a new breakthrough for domestic laparoscopic surgical robot, a high-end medical equipment, to enter into the international market.

IMPACT ON THE COMPANY

As the first domestic laparoscopic surgical robot to have received overseas certifications, Toumai's obtaining of the EU CE mark represents the international market's full recognition of its leading technical strengths and product performance, laying an important foundation for Toumai's future commercialisation and exploration of large-scale clinical applications in the European market and even the global market. This also marks the official arrival of the Chinese surgical robot comprehensive intelligent surgical solution that can prolong and reshape lives in the minimally invasive surgery field across the globe, creating a new era for the internationalisation of domestic surgical robot industry.

Toumai, on behalf of China's laparoscopic surgical robots, is the first to be introduced to the international mainstream market, and leads the innovation and breakthrough of domestic laparoscopic surgical robots in multi-disciplinary clinical applications, remote technological innovation and international market development, proactively carries out domestic and overseas resources integration and global layout and competes with industry peers from all over the world to inject ample momentum into the innovation and development of the global surgical robot industry, benefitting global patients with intelligent manufacturing in China and continues to achieve our belief to "Make Surgery Easier, Safer, and Less Invasive".

Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 9 May 2024

As at the date of this announcement, the executive director is Dr. He Chao, the non-executive directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.